This activity is supported by an unrestricted educational grant from Genentech, a member of the Roche Group.
Upon completion of this activity, the participant should be able to:
Provided by
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, you must read the activity in its entirety, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
David A. Eichenbaum, MD, FAAO (Moderator)
Collaborative Associate Professor
Department of Ophthalmology
University of South Florida Morsani College of Medicine
Director of Research
Retina Vitreous Associates of Florida
Tampa, Florida
David Boyer, MD
Retinal Surgeon
Retina Vitreous Associates Medical Group
Adjunct Clinical Professor Ophthalmology
University of Southern California
Keck School of Medicine
Los Angeles, CA
Aleksandra V. Rachitskaya, MD
Assistant Professor of Ophthalmology
Cole Eye Institute, Cleveland Clinic
Cleveland, OH
Carl Regillo, MD
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, PA
Lejla Vajzovic, MD
Director, Duke Surgical Vitreoretinal Fellowship Program
Director, Duke Eye Center Continuing
Medical Education
Associate Professor of Ophthalmology
Duke University School of Medicine
Duke Eye Center
Durham, NC
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
David A. Eichenbaum, MD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Allergan, EyePoint Pharmaceuticals, Genentech, Gyroscope, IvericBio, Kodiak, Notal Vision, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Alkahest, AsclepiX, Bayer, Chengdu, Gemini, Genentech, Gyroscope, lonis, lvericBio, Kodiak, Mylan, NGM, Novartis, Opthea, and Regeneron Pharmaceuticals. Speaker’s Bureau: Allergan, Bayer, DORC, EyePoint Pharmaceuticals, Genentech, and Novartis.
David Boyer, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Acucela, Adverum Biotechnologies, Aerie Pharmaceuticals, Aerpio, Alcon Vision, Alkahest, Allegro, Allergan, Amydis, Annexon Biosciences, Apellis Pharmaceuticals, AsclepiX Therapeutics, Bausch + Lomb, Bayer, Biogen, BioMotiv, Boehringer-Ingelheim Pharmaceuticals, Cell Care Therapeutic, Chengdu Kanghong Biotechnology, Clearside Biomedical, Daiichi Sankyo, EyePoint Pharmaceuticals, Galimedix Therapeutics, Genentech, GenSight Biologics, Glaukos, GlaxoSmithKline, GrayBug Vision, jCyte, Kala Pharmaceuticals, Iconic Therapeutics, Interface Biologics, Ionis Pharmaceuticals, Lineage Cell, LumiThera, NGMB Biopharma, Novartis Ophthalmics, Ocular Therapeutix, Ocugen, Ocuphire Pharma, Optos, OptoVue, Ora, Orbit Biomedical, Oxurion, pSivida, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Regenxbio, Regulus Therapeutics, Roche, Samumed, Santen, SciFluor Life Sciences 5, Semathera, Shire (Takeda), Stealth BioTherapeutics, and Thea. Stock/Shareholder: Allegro and DigiSight (Verana Health).
Aleksandra V. Rachitskaya, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Carl Zeiss Meditec, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Genentech, and Novartis.
Carl Regillo, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, Allergan, Genentech, Kodiak, and Novartis. Grant/Research Support: Adverum, Allergan, Genentech, Kodiak, Novartis, Regeneron Pharmaceuticals, and Regenxbio.
Lejla Vajzovic, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Alimera Sciences, Allergan, Bausch + Lomb, DORC, Genentech, Gyroscope, Novartis, and Oculus Surgical.
The Evolve staff and planners have no financial relationships with commercial interests.
Michelle Dalton, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Retina Today, or Genentech.
